- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02349568
The Cost Effectiveness of Endoscopic Ultrasound ( EUS ) Based Strategy in Diagnosis of Common Bile Duct Stones
The Cost Effectiveness Between EUS-based Strategy Versus Endoscopic Retrograde Cholangiopancreatography ( ERCP )-Based Strategy in Diagnosis of Common Bile Duct Stones in Patients With Intermediate Risk: a Study in Developing Country.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Background: Multiple reports showed the efficacy of EUS comparable to ERCP in the diagnosis of CBD stone. The EUS-based strategy has provided the cost saving in diagnosis of CBD stone in patients with intermediate risk in previous studies in western population. There were multiple parameters involved the cost effectiveness analysis included cost of ERCP, cost of EUS, prevalence of CBD stones, the sensitivity and specificity of EUS and the rate of complications related to EUS and ERCP. These parameter may vary from center to center and from region to region.
Aims: To assess the cost effectiveness of EUS based strategy versus ERCP based strategy in diagnosis of CBD stones in patients with intermediate risk in a developing country.
Method : A prospective study in 141 patients with suspected CBD stones based on clinical, biochemical and imaging by trans-abdominal ultrasonography or computed abdominal tomography. All patients underwent EUS. All patients with high risk for CBD stone underwent ERCP after the EUS. For patients with intermediate risk for CBD stone, ERCP's were done at the discretion of the attending physicians. For patients with ERCP done, the diagnosis of CBD stone was confirmed by ERCP demonstration of CBD stone. In patients with intermediate risk without ERCP done, clinical follow up to assess biliary symptoms and liver function test as surrogated markers for CBD stone at 3 months interval for one year were done. The false negative rate in patients with EUS and ERCP done in this study was used to estimate the false negative rate in patients in clinical surrogated group.
Definition: High risk of CBD stones was defined when CBD stone was detected by US/CT or dilated duct with abnormal liver function test ( LFT ). Intermediate risk of CBD stones was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
Cost analysis :The cost of making diagnosis of CBD stone excluding all costs of treatment was analyzed. The cost of all patients with suspected CBD stones undergoing ERCP was calculated and compared with the strategy of EUS follow by ERCP. The cost was evaluated by (1) mean costs of EUS and ERCP based on the actual cost in our center which included costs of medical staffs, disposable materials, drugs, equipment amortization and maintenance. (2) cost associated with complications induced by the procedure.
Statistical analysis: Test performance of the endoscopic ultrasound in diagnosis of CBD stones was analyzed with two by two tables. The sensitivity, specificity, positive and negative predictive values were calculated.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Songkhla
-
Hatyai, Songkhla, Thailand, 90110
- NKC Institues of Gastroenterology and Hepatology, Prince of Songkla University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- history of biliary pain or recent cholangitis
- acute pancreatitis
- abnormal liver function test
- dilatation of CBD and or CBD stone detected by trans-abdominal ultrasound and or computed tomography.
Exclusion Criteria:
- unstable hemodynamics
- severe coagulopathy
- refusal to participate
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
High risk group
High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
|
Patients with high risk underwent EUS examination under conscious sedation.
EUS was examined from second part of duodenum up to duodenal bulb.
All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session.
The ERCPs were performed in standard manner.
All patients were contacted by phone on day 1, 3 and 30 after the procedure.
Andre navn:
|
Intermediate risk group
Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
|
Patients with intermediate risk underwent EUS examination under conscious sedation.
EUS was examined from second part of duodenum up to duodenal bulb.
ERCPs were done at the discretion of the attending physicians.
The ERCPs were performed in standard manner.
The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The cost of making diagnosis of CBD stone
Tidsramme: within 12 months after EUS
|
The cost of making diagnosis of CBD stone will be measured as the difference in the cost of all patients undergoing ERCP and ERCP follow by EUS intervention.
The cost was evaluated by (1) mean costs of EUS and ERCP based on the actual cost in our center which included costs of medical staffs, disposable materials, drugs, equipment amortization and maintenance.
(2) costs associated with complications induced by the procedure.
|
within 12 months after EUS
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The accuracy of EUS in diagnosis of CBD stone
Tidsramme: within 12 months after EUS
|
This will be measured as proportion of patients who encounter a correctly diagnosis of CBD stone by EUS.
Positive EUS finding was confirmed by ERCP.
Negative EUS finding was confirmed by ERCP or absence of symptoms for 12 months.
|
within 12 months after EUS
|
The safety of EUS and ERCP procedure
Tidsramme: within 1 months
|
This will be measured as proportion of patients who encounter a procedural complication (%) during EUS and ERCP that includes pancreatitis, perforation or hemorrhage
|
within 1 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Bancha Ovartlarnporn, MD, NKC Institue of Gastroenterology and Hepatology, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkla, Thailand.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EC-55-066-21-1-2
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på High risk group
-
Sun Yat-sen UniversityFullført
-
Chinese University of Hong KongFullført
-
China-Japan Friendship HospitalUkjent
-
Beth Israel Deaconess Medical CenterMassachusetts Institute of Technology; TriNetX, LLCAktiv, ikke rekrutterendeAdenokarsinom i bukspyttkjertelen | Prediktiv kreftmodellForente stater
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)RekrutteringFall-RisikoForente stater
-
Vanderbilt University Medical CenterRekrutteringGenetisk sykdomForente stater
-
University of MichiganNational Institute on Aging (NIA)FullførtSunn aldring | Mild kognitiv sviktForente stater
-
University of ChicagoRekrutteringProstatakreftForente stater
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA)Fullført
-
Shengjing HospitalRekruttering